scholarly journals Management of Hepatitis C in Dialysis Dependent Patients.

2021 ◽  
Vol 5 (3) ◽  
pp. 74-77
Author(s):  
Fawad Khalid ◽  
Muhammad Omair Ansar
Keyword(s):  
Hepatitis C ◽  
Antiviral Therapy ◽  
Maintenance Hemodialysis ◽  
Dialysis Unit ◽  
Direct Acting Antiviral ◽  
Hcv Prevalence ◽  
The Status ◽  
Current Availability ◽  
Almost All ◽  
Direct Acting

Prevalence of Hepatitis C (HCV) is quite high in Pakistan and in particular among maintenance hemodialysis (MHD) patients. HCV is associated with increasing morbidity and mortality among MHD patients. The current availability of direct acting antiviral therapy has changed the canvas for HCV prevalence in many countries. Aim of our study was to evaluate the status of HCV prevalence and its management at our center. Methods:  This descriptive study was conducted at Nawaz Sharif Kidney Hospital Swat, Pakistan to evaluate the seroprevalence of HCV among MHD patients. Data regarding HCV status, PCR positivity and number of patietns on active treatment were evaluated. Results: A total of 109 patients were undergoing MHD in this study. The prevalence of patient who had HCV was 40 (36.6%).  All patietns had PCR done and out of them PCR was positive in 28 Patients. All except 4 of the 28 patients had been started on HCV treatment with direct antiviral therapy for HCV.  Conclusion: almost all of HCV PCR positive patients were being treated  with DAA in our dialysis unit.

Changes in Serum Level of Autotaxin with Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Khaled Mohamed Hussein Abdelwahab ◽  
Shereen Abou Bakr Saleh ◽  
Ghada Abdelrahman Ahmed ◽  
Asmaa Mady Gomaa Mady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Serum Level ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Post Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Background Hepatitis C virus virus is global health burden and major health hazard in Egypt, since the virus is the etiological factor of chronic hepatitis. Hepatitis C virus (HCV) accounts for approximately 15%-20% cases of acute hepatitis. After acute infection, around 50% to 80% of HCV patients will develop chronic infection. Approximately, HCV infects 170 million individuals worldwide). Chronic hepatitis C (CHC) patients are at high risk to develop lifethreatening complications, including cirrhosis in 20% of cases and hepatocellular carcinoma. Objectives The aim of this study was to validate Changes in serum level of autotaxin in patients with chronic hepatitis C before and after antiviral treatment. Patients and methods This study was designed as a prospective observational cohort study to evaluate Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C before (baseline) and after (sustained virologic response week 12) treatment. This prospective study was conducted on 48 chronic HCV infected patients eligible for antiviral treatment with direct acting antivirals, agreeable to regular follow up, recruited from Hepatology and virology outpatient clinic at DMNI (Damanhour Medical National Institute) during the period from September 2018 till Mars 2019. Results This study showed that Autotaxin level significantly decreased from baseline to 12 weeks post-treatment. ATX therefore represents a novel non-invasive biomarker for liver fibrosis and a prognostic indicator of disease activity. Conclusion Serum Autotaxin was found to be higher in chronic hepatitis c and ATX levels became significantly decreased from baseline to 12 weeks post-treatment with direct acting antiviral drugs in patients achieving a SVR.

Sign in / Sign up

Export Citation Format

Share Document